Tetraphase Pharmaceuticals Inc. (TTPH)

0.42
NASDAQ : Health Technology
Prev Close 0.41
Day Low/High 0.40 / 0.44
52 Wk Low/High 0.40 / 3.66
Avg Volume 584.00K
Exchange NASDAQ
Shares Outstanding 54.26M
Market Cap 21.98M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria...

Tetraphase Doses First Patient In Phase 3 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Doses First Patient In Phase 3 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the dosing of the first patient in its Phase 3 clinical trial of its lead drug candidate eravacycline for the treatment of complicated intra-abdominal ...

Tetraphase Reports Second Quarter 2013 Financial Results

Tetraphase Reports Second Quarter 2013 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended June 30, 2013.

Tetraphase: Another Good Investment In Hot Antibiotic Market

Tetraphase: Another Good Investment In Hot Antibiotic Market

The company's antibiotic won't have late-stage study data available until 2015 but it's worth the wait.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

FDA Grants QIDP Designation To Eravacycline, Tetraphase’s Lead Antibiotic Product Candidate

FDA Grants QIDP Designation To Eravacycline, Tetraphase’s Lead Antibiotic Product Candidate

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) today announced that the U.

Small-Cap Biotechs Pursue IPOs Fastest in Decade

Small-Cap Biotechs Pursue IPOs Fastest in Decade

The bar for progress has been lowered for biotechs looking to enter the market.

Top Insider Trades: TTPH PRTS APA FB

Top Insider Trades: TTPH PRTS APA FB

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

Medical IPOs - Are They Healthy?

Medical IPOs - Are They Healthy?

IPO Desktop President Francis Gaskins and TheStreet's Debra Borchardt look at the Enanta Pharmaceuticals and Tetraphase Pharmaceuticals offerings.

TheStreet Quant Rating: D (Sell)